Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

vilobelimab

vilobelimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Gohibic POWDER FOR INJECTION, INTRAVENOUS 200mg/20mL      
Comments:

The FDA issued an Emergency Use Authorization (EUA) for the use of Gohibic injection for the treatment of COVID-19. Not currently approved for use at Huntsville Hospital.

 

Reviewed: October 2023

 

Vilobelimab (Gohibic)

 

 

Last updated: Nov. 22, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved